Drug intelligence / Profile preview

ensereptide

Development stage
Phase 2
Lead developer
Promore Pharma
Modality
Peptides
Administration
Local Injection, Intradermal
01

Overview

Ensereptide (PXL01) is a synthetic peptide derived from human lactoferrin, an iron-binding glycoprotein found in milk and mucosal secretions. It is being developed primarily for the prevention of post-surgical adhesions, particularly after tendon repair surgery in the hand, and for the prevention of dermal scarring after surgery or trauma. The drug acts through several mechanisms including immunomodulation—by inhibiting pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, and TNF-α—and enhancement of fibrinolytic activity by inhibiting plasminogen activator inhibitor-1 (PAI-1). These actions reduce inflammation and promote fibrinolysis at surgical sites to prevent adhesion formation and scar tissue development. Ensereptide is typically formulated with sodium hyaluronate as a carrier to provide local delivery and sustained release at the site of injury[1][3][4][5][7].

Other names
ensereptide
02

Targets

PAI-1 (Plasminogen activator inhibitor type 1)IL8 (C-X-C Motif Chemokine Ligand 8)TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)PRG4 (Proteoglycan 4)IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on ensereptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ensereptide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call